<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106807</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18173</org_study_id>
    <nct_id>NCT01106807</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne</brief_title>
  <official_title>Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in
      reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice
      daily applications. The study will also evaluate the safety of the study products using
      tolerance and adverse event data.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total acne lesion count</measure>
    <time_frame>6 weeks</time_frame>
    <description>change in total number of acne lesion count from baseline to end of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change of acne lesion count</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percent change of acne lesion count from baseline to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion counts- Inflammatory</measure>
    <time_frame>6 weeks</time_frame>
    <description>change in lesion count from baseline at each evaluation visit; efficacy preference at the end of treatment by investigator and subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion count- non-inflammatory</measure>
    <time_frame>6 weeks</time_frame>
    <description>change in lesion count from baseline at each evaluation visit; efficacy preference at the end of treatment by investigator and subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion counts- Inflammatory</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percent change of acne lesion count from baseline at each evaluation visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion count- non-inflammatory</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percent change of acne lesion count from baseline at each evaluation visit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>CD07223 1.5% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07223 0.5% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo vehicle gel</intervention_name>
    <description>500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks</description>
    <arm_group_label>CD07223 1.5% gel</arm_group_label>
    <arm_group_label>CD07223 0.5% gel</arm_group_label>
    <arm_group_label>Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07223</intervention_name>
    <description>500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks</description>
    <arm_group_label>CD07223 1.5% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07223</intervention_name>
    <description>500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks</description>
    <arm_group_label>CD07223 0.5% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel</intervention_name>
    <description>500 microliters Epiduo Gel on one of the half-face for the morning dose</description>
    <arm_group_label>Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject has a clinical diagnosis of acne vulgaris with facial involvement

          -  the subject has at least 15 inflammatory lesions and 25 non-inflammatory lesions
             (excluding the nose) but no more than 2 nodules on the face

        Exclusion Criteria:

          -  subject has a severe acne form or secondary acne form

          -  the number of inflammatory or non-inflammatory lesions on one half-face is greater
             than twice the number on the other half-face

          -  the subject has a known allergy or sensitivity to any of the components of the study
             products

          -  subject is not willing to respect wash-out periods for topical and/or systemic
             treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceuticals</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialist PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TKL Research</name>
      <address>
        <city>Rochelle Park</city>
        <state>New Jersey</state>
        <zip>07662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Education and Research Foundation, Inc</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <disposition_first_submitted>January 19, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 19, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2011</disposition_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

